Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FBLG
stocks logo

FBLG

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.092
+2.78%
--
--
-0.095
-32.14%
--
--
-0.095
-20.83%
Estimates Revision
The market is revising No Change the revenue expectations for FibroBiologics, Inc. (FBLG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -27.62%.
EPS Estimates for FY2025
Revise Upward
up Image
+3.83%
In Past 3 Month
Stock Price
Go Down
down Image
-27.62%
In Past 3 Month
Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.393
sliders
Low
4.00
Averages
4.50
High
5.00
Current: 0.393
sliders
Low
4.00
Averages
4.50
High
5.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$10 -> $5
2025-11-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $5
2025-11-05
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on FibroBiologics to $5 from $10 and keeps a Buy rating on the shares. The firm adjusted the company's model to reflect an updated share count and tempered factor of patients receiving FibroBiologics' novel diabetic foot ulcer treatment pending further clinical validation.
H.C. Wainwright
Matthew Caufield
Buy
downgrade
$12 -> $10
2025-08-05
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$12 -> $10
2025-08-05
downgrade
Buy
Reason
H.C. Wainwright analyst Matthew Caufield lowered the firm's price target on FibroBiologics to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's progress continues across therapeutic fibroblast development.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-04-09
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-04-09
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-04-01
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$12
2025-04-01
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$12
2025-04-01
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$16
2025-03-04
Reason
D. Boral Capital
Jason Kolbert
Price Target
$16
2025-03-04
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fibrobiologics Inc (FBLG.O) is -0.91, compared to its 5-year average forward P/E of -8.90. For a more detailed relative valuation and DCF analysis to assess Fibrobiologics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.90
Current PE
-0.91
Overvalued PE
0.97
Undervalued PE
-18.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

FBLG News & Events

Events Timeline

(ET)
2025-12-10
08:50:00
FibroBiologics Submits New Patent Application for Cartilage Repair
select
2025-11-26 (ET)
2025-11-26
08:37:45
FibroBiologics reveals settlement of remaining debt
select
2025-11-24 (ET)
2025-11-24
09:06:05
FibroBiologics sets price for 4.48 million shares at $0.335 in direct registered offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-11Benzinga
FibroBiologics Submits New Patent for Fibroblast Technology to Expand Further into Orthopedic Field

  • Patent Application Submission: FibroBiologics, Inc. submitted a new patent application for a fibroblast-derived therapy platform aimed at treating orthopedic and musculoskeletal conditions, enhancing protection for their fibroblast technology.

  • Preclinical Study Results: Preclinical studies indicate that fibroblast-based constructs and chondrocyte spheroids effectively integrate with native tissue and promote regeneration in models of disc and joint degeneration.

  • Recent Financial Activity: In November, the company completed a registered direct offering of 4.48 million shares, raising approximately $1.5 million, and also issued unregistered warrants for the same number of shares.

  • Trial Approvals: FibroBiologics received approval in Australia for a Phase 1/2 trial of CYWC628, a fibroblast cell-based therapy for refractory diabetic foot ulcers, allowing the enrollment of 120 patients.

[object Object]
Preview
9.5
11-26Newsfilter
FibroBiologics Pays Off $15M Convertible Debt, Focuses on Clinical Trials
  • Debt Repayment: FibroBiologics has paid off $15 million in convertible debt, eliminating its obligations to Yorkville, which enhances the company's financial stability and allows for a greater focus on clinical trials.
  • Clinical Trial Advancement: The company plans to initiate its Phase 1/2 clinical trial for the CYWC628 product candidate targeting diabetic foot ulcer patients in early 2026, marking a significant milestone in its R&D progress.
  • New Drug Application Preparation: FibroBiologics is preparing to submit Investigational New Drug applications for CYPS317 and CYMS101, aimed at treating psoriasis and multiple sclerosis, further expanding its product pipeline and enhancing market competitiveness.
  • Strategic Investment Opportunities: Despite repaying its debt, FibroBiologics retains the option to sell an additional $10 million of common stock under the SEPA agreement before 2026, demonstrating the company's flexibility in capital markets and potential growth opportunities.
[object Object]
Preview
4.5
11-25TipRanks
VTI ETF Daily Report—November 25, 2025

  • Vanguard Total Stock Market ETF Overview: The VTI ETF provides broad exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.

  • Market Performance: On Monday, VTI rose by 1.21%, while the Nasdaq Composite and S&P 500 increased by 2.7% and 1.5%, respectively, as investor confidence grew ahead of potential Federal Reserve policy easing.

  • Investment Trends: Despite a slight decline of 0.26% over the past five days, VTI is up 13% year-to-date, with a three-month average trading volume of 4.06 million shares and recent net inflows of $246 million.

  • Analyst Consensus and Potential: VTI is rated as a Moderate Buy with an average price target of $387.05, suggesting a 17.7% upside, while its Smart Score of seven indicates expected performance in line with the broader market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fibrobiologics Inc (FBLG) stock price today?

The current price of FBLG is 0.3929 USD — it has increased 12.94 % in the last trading day.

arrow icon

What is Fibrobiologics Inc (FBLG)'s business?

FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

arrow icon

What is the price predicton of FBLG Stock?

Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fibrobiologics Inc (FBLG)'s revenue for the last quarter?

Fibrobiologics Inc revenue for the last quarter amounts to -5.04M USD, increased 50.30 % YoY.

arrow icon

What is Fibrobiologics Inc (FBLG)'s earnings per share (EPS) for the last quarter?

Fibrobiologics Inc. EPS for the last quarter amounts to -3978000.00 USD, increased 52.01 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fibrobiologics Inc (FBLG)'s fundamentals?

The market is revising No Change the revenue expectations for FibroBiologics, Inc. (FBLG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -27.62%.
arrow icon

How many employees does Fibrobiologics Inc (FBLG). have?

Fibrobiologics Inc (FBLG) has 13 emplpoyees as of December 13 2025.

arrow icon

What is Fibrobiologics Inc (FBLG) market cap?

Today FBLG has the market capitalization of 26.72M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free